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Introduction
Despite three decades of successful, predominantly phenotype-driven, discovery of the 
genetic causes of monogenic disorders 1, up to half of children with severe developmental 
disorders (DDs) of likely genetic origin remain without a genetic diagnosis. Especially 
challenging are those disorders rare enough to have eluded recognition as a discrete clinical 
entity, those whose clinical manifestations are highly variable, and those that are difficult to 
distinguish from other, very similar, disorders. Here we demonstrate the power of embracing 
an unbiased genotype-driven approach 2 to identify subsets of patients with similar 
disorders. By studying 1,133 children with severe, undiagnosed DDs, and their parents, 
using a combination of exome sequencing 3–11 and array-based detection of chromosomal 
rearrangements, we discovered 12 novel genes causing DDs. These newly implicated genes 
increase by 10% (from 28% to 31%) the proportion of children that could be diagnosed. 
Clustering of missense mutations in six of these newly implicated genes suggest that normal 
development is being perturbed by an activating or dominant negative mechanism. Our 
findings demonstrate the value of adopting a comprehensive strategy, both genomewide and 
nationwide, to elucidating the underlying causes of rare genetic disorders.
We established a network to recruit 1,133 children (median age 5.5, Extended Data Fig. 1A) 
with diverse, severe undiagnosed DDs, through all 24 regional genetics services of the UK 
National Health Service and Republic of Ireland. Among the most commonly observed 
phenotypes (Extended Data Fig. 1B, Supplementary Table 1) were intellectual disability or 
developmental delay (87% of children), abnormalities revealed by cranial MRI (30%), 
seizures (24%), and congenital heart defects (11%). These children are predominantly 
(~90%) of Northwest European ancestry (Extended Data Fig. 1C), with 47 pairs of parents 
(4.1%) exhibiting kinship equivalent to, or in excess of second cousins (Extended Data Fig. 
1D, Supplementary Information). In most families (849/1,101), the child was the only 
affected family member, but 111 children had one or more parents with a similar DD, and 
124 had a similarly affected sibling (Supplementary Information). Prior clinical genetic 
testing would have already diagnosed many children with easily recognized syndromes, or 
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large pathogenic deletions and duplications, enriching this research cohort for less distinct 
syndromes, and novel genetic disorders.
We exome sequenced 1,133 affected children and their parents, from 1,101 families, 
representing 1,071 unrelated children and 30 sibships. We also performed exome-focused 
array comparative genomic hybridization (exome-aCGH) on the children (N=1,009) and UK 
controls (N=1,013) and genome-wide genotyping on the trios (N=1,006) to identify 
deletions, duplications, uniparental disomy (UPD) and mosaic large chromosome 
rearrangements. From our exome sequencing and exome-aCGH data, we detected an 
average of 19,811 coding or splicing single nucleotide variants (SNVs), 491 coding or 
splicing indels and 148 Copy Number Variants (CNVs) per child (Supplementary 
Information). From analyses of the genotyping array data 12 we identified 6 children with 
UPD and 5 children with mosaic large chromosomal rearrangements (Supplementary 
Information). The SNVs, indels and CNVs were analysed jointly in the following analyses, 
allowing, for example, the identification of compound heterozygous CNVs and SNVs 
affecting the same gene.
We discovered 1,618 de novo variants (1,417 SNVs, 114 indels and 87 CNVs) in coding and 
non-coding regions (Supplementary Tables 2 and 3), of which 1,596 (98.6%) were validated 
using a second, independent assay, and the remainder were validated clinically. This 
represents an average of 1.12 de novo SNVs and 0.09 de novo indels in coding or splicing 
regions per child, which is within the range of similar studies 3–11. The distribution of de 
novo SNVs and indels per child closely approximated the Poisson distribution expected for 
random mutational events (Extended Data Fig. 2).
We classified 28% (N=317) of children with likely pathogenic variants (Supplementary 
Table 4 and 13) in 1,129 robustly implicated DD genes (published before Nov 2013), or with 
pathogenic deletions or duplications. The majority of these diagnoses involved de novo 
SNVs, indels or CNVs (Table 1). Females had a significantly higher diagnostic yield of 
autosomal de novo mutations than males (p=0.01, Fisher exact test). Among the single gene 
diagnoses, most DD genes (95/148) were only observed once, although eight (ARID1B, 
SATB2, SYNGAP1, ANKRD11, SCN1A, DYRK1A, STXBP1, MED13L) each accounted 
for 0.5-1% of children in our cohort (Extended Data Figure 3). For 17 of these children we 
identified two different genes with pathogenic variants, resulting in a composite clinical 
phenotype.
Analyses that assess the enrichment in patients of a particular class of variation, so-called 
‘ burden analyses’ , both highlight classes of variants for detailed analysis, and enable 
estimation of the proportion of a particular class of variant that is likely to be pathogenic. We 
observed a significant (p=0.0004) burden of 87 de novo CNVs in the 1,133 DD children 
compared to 12 in 416 controls (Scottish Family Health Study14) despite most children 
(77%) having previously had clinical microarray testing (Extended Data Figure 4).
We used gene-specific mutation rates that account for gene length and sequence context 15 
to assess the burden of different classes of de novo SNVs and indels (Supplementary 
Information). We observed no significant excess of any functional class of de novo SNVs or 
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indels in autosomal recessive DD genes (Extended Data Figure 5), suggesting that few of 
these mutations are causally implicated. By contrast, we observed a highly significant excess 
of all ‘ functional’  classes (coding and splice site variants excepting synonymous changes) of 
de novo SNVs and indels in the dominant and X-linked DD genes (Extended Data Figure 5) 
within which de novo mutations can be sufficient to cause disease. Not all protein-altering 
mutations in known dominant and X-linked DD genes will be pathogenic, and these burden 
analyses inform estimates of positive predictive values for different classes of mutations. 
The remaining, non-DD, genes in the genome also exhibit a more modest, but significant, 
excess of functional, but not silent, de novo SNVs and indels (Extended Data Figure 5).
We observed 96 genes with recurrent, functional mutations (Figure 1A), a highly significant 
excess compared to the expected number derived from simulations (median=55, 
Supplementary Information). This enrichment is even more pronounced (observed:29, 
expected:3) for recurrent LoF mutations (Figure 1B). Among undiagnosed children, we 
observed an excess of 22 genes (observed: 45, expected: 23) with recurrent functional 
mutations (Figure 1A), and an excess of 8 genes (observed:9, expected:1) with recurrent LoF 
mutations (Figure 1B), implying that an appreciable fraction of these recurrently mutated 
genes are novel DD genes.
To identify individual genes enriched for damaging de novo mutations (Supplementary 
Information), we tested for a gene-specific overabundance of either de novo LoF mutations 
or clustered functional de novo mutations in 1,130 children (excluding one twin from each 
of 3 identical twin-pairs). To increase power to detect DD genes, we also meta-analysed our 
data with published de novo mutations from 2,347 DD trios with intellectual disability 4,9, 
epileptic encephalopathy 3, autism 6–8,10, schizophrenia 5, or congenital heart defects 11 
(the ‘ meta-DD’  dataset). These analyses (Figure 2) successfully re-discovered 20 known DD 
genes at genome-wide significance (p < 1.31 × 10-6, a Bonferroni p value of 0.05 corrected 
for 38,504 tests [Supplementary Information]). Thus, despite the broad phenotypic 
ascertainment in these datasets, we can robustly detect DD genes solely on statistical 
grounds.
To increase our power to detect novel DD genes, we repeated the gene-specific analysis 
described above excluding the 317 individuals with a known cause of their DD. In this 
analysis the statistical genetics evidence was integrated with phenotypic similarity of 
patients, available data on model organisms and functional plausibility. We identified 12 
novel disease genes with compelling evidence for pathogenicity (Table 2), nine of which 
exceeded the genome-wide significance threshold of 1.36 × 10-6 (Supplementary 
Information), with the remaining three genes (PCGF2, DNM1 and TRIO) just below this 
significance threshold. The two children with identical Pro65Leu mutations in PCGF2, 
which encodes a component of a Polycomb transcriptional repressor complex, share a 
strikingly similar facial appearance representing a novel and distinct dysmorphic syndrome. 
DNM1 was previously identified as a candidate gene for epileptic encephalopathy (EE) 3. 
Two of the three children we identified with DNM1 mutations also had seizures, and a 
heterozygous mouse mutant manifests seizures 16. In addition to two de novo missense 
SNVs in TRIO, we identified an intragenic de novo 82kb deletion of 16 exons. For several 
of these novel DD genes, the meta-DD analysis increased the significance of enrichment. 
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For example, a total of five de novo LoF variants in POGZ were identified, two from our 
cohort, two from recent autism studies and one from a recent schizophrenia study. We also 
identified six genes with suggestive statistical evidence of being novel DD genes, defined as 
being a p value for mutation enrichment less than 1 × 10-4 and being plausible from a 
functional perspective (Extended Data Table 1). We anticipate that the majority of these 
genes will eventually accrue sufficient evidence to meet the stringent criteria we defined 
above for declaring a novel DD gene.
Strikingly, we observed identical missense mutations in unrelated, phenotypically similar, 
patients for four of these novel DD genes (PCGF2, COL4A3BP, PPP2R1A and PPP2R5D), 
and for a fifth gene, BCL11A, we identified highly significant clustering of non-identical 
missense mutations (Figure 3). We hypothesise that the mutations in some of these genes 
may be operating by either dominant negative or activating mechanisms. This hypothesis is 
supported by prior functional evidence for several of the mutated amino acids. The three 
identical Ser132Leu mutations in COL4A3BP, which encodes an intracellular transporter of 
ceramide, remove a serine that when phosphorylated down-regulates transporter activity 
from the ER to the golgi 17, presumably resulting in intra-cellular imbalances in ceramide 
and its downstream metabolic pathways. The two mutated amino acids (Arg182Trp and 
Pro179Leu) in PPP2R1A, which encodes the scaffolding A subunit of the Protein 
Phosphatase 2 complex, have been previously identified as sites of driver mutations in 
endometrial and ovarian cancer 18. It has previously been shown that mutating either of 
these two residues results in impaired binding of B subunits of the complex 18. Intriguingly, 
PPP2R5D encodes one of the possible B subunits of the same Protein Phosphatase 2 
complex, suggesting that the clustered missense mutations (Pro201Arg and Glu198Lys) in 
this gene may similarly perturb interactions between subunits of this complex. Further 
functional studies will be required to confirm this hypothesis.
We assessed transmission biases of potentially pathogenic inherited SNVs in our probands 
(Supplementary Information) and observed a genome-wide trend (p=0.015) towards over-
transmission to probands of very rare (MAF < 0.0005%) LoF variants, but not damaging 
missense variants. We also observed a 1.8-fold enrichment (p=0.04) of rare (MAF<5%) 
biallelic LoF variants (Supplementary Table 5) among probands without a likely dominant 
cause of their disorder, compared to those with either a diagnostic de novo mutation or an 
affected parent. Again we saw no enrichment in biallelic damaging missense variants 
(Extended Data Table 2), consistent with a similar observation in children with autism 19. 
These observations imply that although inherited LoF variants (both monoallelic and 
biallelic) are likely contributing to DD in our patients, much larger sample sizes will be 
required to pinpoint specific DD genes in this way.
To direct future, detailed functional experiments on the developmental role of a subset of 
candidate genes from this study we used two approaches. First, knockdown-induced 
phenotypes were recorded in early zebrafish development. Second we performed a 
systematic review of perturbed gene function in human, mouse, xenopus, zebrafish and 
drosophila. In both approaches the animal phenotypes were compared to those seen in 
individuals in our cohort
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We undertook an antisense-based loss of function screen in zebrafish to assess 32 candidate 
DD genes with de novo LoF, de novo missense or biallelic LoF variants from exome 
sequencing (Supplementary Information and Supplementary Table 6). These candidate genes 
corresponded to 39 zebrafish orthologues. Knockdowns of these zebrafish genes were 
repeated at least twice and all morpholinos were co-injected with tp53 morpholino to 
eliminate off-target toxicity. Successful knockdown of the targeted mRNA could be 
confirmed using RT-PCR for 82.4% of genes (28/34) and 9/11 (82%) of genes that were 
tested gave an equivalent phenotype when knocked down by a second, independent 
morpholino. Knock-down of at least one or a pair of zebrafish orthologues of 65.6% of 
candidate DD genes (21 out of 32) resulted in perturbed embryonic and larval development 
(Figure 4, Extended Data Table 3, Supplementary Data and Supplementary Table 7). Large-
scale mutagenesis 20 and morpholino 21 studies suggest knockout or knockdown of 6-12% 
genes give developmental phenotypes, suggesting at least a five-fold enrichment of 
developmentally non-redundant genes among the 32 selected for modelling. We then 
compared the phenotypes of the zebrafish morphants to those of the DDD individuals with 
de novo mutations or biallelic LoF variants in the orthologous genes (Extended Data Table 
3). 11/21 (52.4%) of the genes were categorised as strong candidates based on phenotypic 
similarity (Figure 4A). 7/11 were potential microcephaly genes whose gene knockdown in 
zebrafish gives significant reductions in both head measurements, and neural tissue (Figure 
4B, Supplementary Information). 6/21 (28.6%) genes resulted in severe morphant 
phenotypes which could not be meaningfully linked to patient phenotypes. As many of our 
candidate DD genes carried heterozygous LoF variants (de novo mutations), it is to be 
expected that the severity of LoF phenotypes in zebrafish may exceed that observed in our 
patient cohort. The genes with proven non-redundant developmental roles can reasonably be 
assigned higher priority for downstream functional investigations and genetic analyses.
Our systematic review of gene perturbation in multiple species sought both confirmatory and 
contradictory (e.g. healthy homozygous knock-out) evidence from other animal models for 
these 21 apparently developmentally important genes. We identified 16 genes with solely 
confirmatory data, often from multiple different organisms, none with solely contradictory 
data, two with both confirmatory and contradictory evidence and three with no evidence 
either way (Supplementary Table 8).
In summary, our analyses validate a large-scale, genotype-driven strategy for novel DD gene 
discovery that is complementary to the traditional phenotype-driven strategy of studying 
patients with very similar presentations, and is particularly effective for discovering novel 
DDs with highly variable or indistinct clinical presentations. Our meta-analysis with 
previously published DD studies increased power to detect novel DD genes and highlights 
the shared genetic etiologies between diverse neurodevelopmental disorders such as 
intellectual disability, epilepsy, autism and schizophrenia 22. We identified significantly 
more pathogenic autosomal de novo mutations in females compared to males. An increased 
burden of monogenic disease among females with neurodevelopmental disorders has 
become more apparent 23,24, and our observations strengthen this proposition. Further 
investigations are required to assess whether males might be enriched for poly/oligogenic 
causation.
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The 35 patients with pathogenic mutations in the 12 novel DD genes we discovered 
increased our diagnostic yield from 28% to 31%. What, then, are the causes of the DDs in 
the other 69% of patients? The undiagnosed patients are not obviously less severely affected 
than the diagnosed patients (e.g. fewer phenotype terms, older age of recruitment). We 
anticipate that there are many more pathogenic, monogenic, coding mutations in these 
undiagnosed patients that we have detected, but for which compelling evidence is currently 
lacking. This hypothesis is supported by four strands of evidence: (i) modeling statistical 
power suggests that studying ~1,000 trios has only 5-10% power to detect an averagely 
mutable haploinsufficient DD gene (Extended Data Figure 6A, Supplementary Information), 
(ii) the expectation that our power to detect novel DD genes that operate recessively or by 
gain-of-function mechanisms will be lower than for haplosufficient genes, (iii) the 
significant enrichment in undiagnosed patients of functional mutations in genes predicted to 
exhibit haploinsufficiency (Extended Data Figure 6B), and (iv) the strong enrichment for 
developmental phenotypes in the zebrafish knock-down screen.
Given our limited power to detect pathogenic mutations that act through dominant negative 
or activating mechanisms, it was notable that in four of our novel genes (COL4A3BP, 
PPP2R1A, PPP2R5D and PCGF2) we observed identical de novo mutations in unrelated 
trios. Two hypotheses might explain this observation: first, that there is a vast number of 
different gain-of-function mutations, of which we are just scratching the surface in this 
study, or second, that these particular variants are enriched in our cohort due to these 
mutations conferring a positive selective advantage in the germline 25. Analysis of larger 
datasets will be required to assess these hypotheses, although they are not necessarily 
mutually exclusive.
These considerations of the limited power of even nationwide studies such as ours motivate 
the international sharing of minimal genotypic and phenotypic data, for example through the 
DECIPHER web portal (http://decipher.sanger.ac.uk), to provide diagnoses for patients who 
would otherwise remain undiagnosed. Plausibly pathogenic variants observed in 
undiagnosed patients in our study (de novo SNVs, indels and CNVs, and biallelic LoF in 
genes not yet associated with disease) are shared through DECIPHER, and we encourage 
other, comparable studies to adopt a similar approach.
Extended Data
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EDT1
Novel genes with suggestive evidence for a role in DD
Six genes with suggestive evidence to be novel DD genes. The number of unrelated patients with independent functional or LoF mutations in the DDD 
cohort or the wider meta-analysis dataset including DDD patients is listed. The p value reported is the minimum p value from the testing of the DDD 
dataset and the meta-analysis dataset. The dataset that gave this minimal p value is also reported. Mutations are considered to be clustered if the p value of 
clustering of functional SNVs is less than 0.01. Predicted haploinsufficiency is reported as a percentile of all genes in the genome, with ~0% being highly 
likely to be haploinsufficient and 100% very unlikely to be haploinsufficient, based on the prediction score described in Huang et al 26 updated to enable 
predictions for a higher fraction of genes in the genome. NAA10 is already known to cause an X-linked recessive DD in males, but here we identified 
missense mutations in females, suggesting a different, X-linked dominant, disorder.
Evidence Gene de novos DDD (Missense, 
LoF)
de novos Meta (Missense, 
LoF)
P Value Test Mutation Clustering Predicted Haploinsufficiency
De novo enrichment + additional evidence NAA15 1 (0,1) 3 (0,3) 1.64E-06 Meta No 7.5%
ZBTB20 3 (1,2) 3 (1,2) 4.84E-06 DDD No 0.2%
NAA10 2 (2,0) 3 (3,0) 8.28E-06 Meta No 34.1%
TRIP12 3 (1,2) 4(2,2) 2.13E-05 Meta No 3.8%
USP9X 3 (1,2) 3 (1,2) 5.14E-05 DDD No 3.8%
KAT6A 2 (0,2) 2 (0,2) 7.91E-05 DDD No 19.0%
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Biallelic Loss of function and damaging functional 
variants
Rare (MAF < 5%) biallelic loss-of-function and damaging functional variants in uninherited 
diplotypes and probands. ‘ Likely dominant probands’  refers to probands with a reported e 
novo mutation or affected parents, and ‘ other probands’  to all remaining probands. ‘ DDG2P 
Biallelic’  refers to confirmed and probable DDG2P genes with a biallelic mode of 
inheritance. See Supplemental methods for details of variant processing.
Biallelic Variant Types Untransmitted Diplotypes (n=1080) Likely 
Dominant 
Probands 
(n=270)
Other Probands (n=810)
LoF/LoF (Genome-wide) 110 17 86
LoF/Dam (Genome-wide) 87 21 71
Dam/Dam (Genome-wide) 312 90 264
LoF/LoF (DDG2P Biallelic) 1 1 3
LoF/Dam (DDG2P Biallelic) 2 0 6
Dam/Dam (DDG2P Biallelic) 26 7 25
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EDT3
Zebrafish modeling identifies 21 developmentally important candidate genes
This table summarises the 21 genes whose knockdown results in developmental phenotypes in zebrafish. “# patients” column indicates how many patients 
were identified as carrying variants in these genes. Split numbers indicate the breakdown of variant types (eg. for BTBD9, 2/1 is two biallelic LoF and 
one de novo missense carrying patients). A summary of the patient phenotypes is listed, as well as the relevant phenotypes observed in zebrafish 
knockdown experiments. Phenotypic concordance categories indicate the degree of overlap between the zebrafish phenotyping and the patient 
phenotypes. Weak concordance typically is the result of severe, multisystem phenotypes in zebrafish. See Supplemental Materials for more detailed 
phenotype information.
Gene # patients Variant Patient phenotypes Phenotypic concordance Relevant knockdown phenotypes
BTBD9 2/1 Biallelic LoF/De novo 
Missense
Seizures, microcephaly, hypertonia Strong Reduced head size, brain volume
CHD3 1/2 De novo LoF/Missense CNS and craniofacial defects Strong Abnormal head shape
DDX3X 1/3 De novo LoF/Missense Moderately short stature, microcephaly, CNS defects Strong Reduced head size, brain volume
ETFl 1 De novo LoF CNS and craniofacial defects, seizures, microcephaly, 
hypertelorism
Strong Reduced head size, brain volume
FRYL 1 De novo LoF Short stature, craniofacial and cardiac defects Strong Cardiac defects, reduced axis length
PKN2 1 De novo Missense CNS, cardiac, ear, and craniofacial defects, growth 
retardation
Strong Cardiac, craniofacial cartilage, and growth defects
PSMD3 1 De novo Missense Microcephaly, muscular hypotonia, seizures, growth 
abnormality
Strong Reduced head size and neural defects
SCGN 1 Biallelic LoF Seizures, microcephaly, CNS defects Strong Reduced head size, brain volume
SETD5 1 De novo LoF Seizures, CNS and cardiac defects, poor motor 
coordination
Strong Reduced head size, cardiac defects, abnormal 
locomotion
THNSL2 2 Biallelic LoF Microcephaly, CNS and ear defects Strong Reduced head size, brain volume, neural defects
ZRANB1 2 De novo Missense Microcephaly, muscle defects, seizures Strong Reduced heaa size and neural defects
DPEP2 1 Biallelic LoF CNS defects, growth retardation Moderate Growth reduction
PSD2 1 De novo LoF CNS defects, hypertonia, seizures Moderate Abnormal musculature, CNS and locomotion
SAP130 1 De novo LoF Short stature, hypotonia, hypotelorism Moderate Abnormal locomotion
CN0T1 1/1 De novoLoF/Missense Short stature, cardiac, CNS, ear and craniofacial defects Weak Multisystem
DTWD2 1 De novo LoF CNS defects, seizures Weak Multisystem
ILVBL 1 De novo LoF CNS and craniofacial defects Weak Multisystem
NONO 1 De novo LoF CNS and ear defects, hypotonia, growth retardation Weak Multisystem, with otic and growth defects
POGZ 2 De novoLoF CNS and ear defects, hypotonia, seizures, coloboma Weak Multisystem
SMARCD1 1/1 De novoLoF/Missense CNS defects, hypotonia Weak Multisystem
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Gene # patients Variant Patient phenotypes Phenotypic concordance Relevant knockdown phenotypes
WWC1 1 De novo Missense CNS defects, hypertelorism None None Fitzgerald et al.
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EDF1. Characteristics of the families
A. Gestation Adjusted Decimal Age at Last Clinical Assessment. Histogram showing the 
distribution of the gestation adjusted decimal age at last clinical assessment across the 1133 
probands. The dashed red line shows the median age. B. Frequency of HPO Term Usage. 
Bar plot showing, for each used HPO term, the number of times it was observed across the 
1133 proband patient records. C. Projection PCA plot of the 1133 probands. PCA plot of 
1133 DDD probands projected onto a PCA analysis using 4 different HapMap populations 
from the 1000 genomes project. Black: African, Red: European, Green: East Asian, Blue: 
South Asian and the 1133 DDD probands are represented by orange triangles. D. Self 
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Declared and Genetically Defined Consanguinity. Overlaid histogram showing the 
distribution of kinship coefficients from KING comparing parental samples for each trio. 
Green: Trios where consanguinity was not entered in the patient record on DECIPHER. Red: 
Trios consanguinity was declared in the patient record on DECIPHER.
EDF2. Number of Validated de novo SNVs and indels per Proband
Bar plot showing the distribution of the observed number of validated SNVs and indels per 
proband sample, and the expected distribution assuming a Poisson distribution with the same 
mean as the observed distribution.
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EDF3. Number of Diagnoses per Gene
Histogram showing the number of diagnoses per gene for genes with at least two diagnoses 
from different proband samples.
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EDF4. Burden of Large CNVs in 1133 DDD Proband Samples
Plot comparing the frequency of rare CNVs in three sample groups against CNV size. Y-axis 
is the on a log scale. Red: DDD probands who have not had previous microarray based 
genetic testing, Purple: DDD probands who have had negative previous microarray based 
genetic testing Green: DDD controls.
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EDF5. Expected and observed numbers of de novo mutations
The expected and observed numbers of mutations of different functional consequences in 
three mutually exclusive sets of genes are shown, along with the p value from an assessment 
of a statistical excess of observed mutations. The three classes of genes are described in the 
main text.
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EDF6. Haploinsufficiency analyses
A. Saturation analysis for detecting haploinsufficient DD genes. A boxplot showing the 
distribution of statistical power to detect a significant enrichment of LoF mutations across 
18,272 genes in the genome, for different numbers of trios studied, from 1,000 trios to 
12,000 trios. B. Distribution of haplinsufficiency scores in selected sets of de novo 
mutations. Violin plot of haploinsufficiency scores in five sets of de novo mutations: Silent - 
all synonymous mutations, Diagnostic - mutations in known DD genes in diagnosed 
individuals, Undiagnosed_Func - all functional mutations in undiagnosed individuals, 
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Undiagnosed_LoF - All LoF mutations in undiagnosed individuals, Undiagnosed_recur - 
mutations in genes with recurrent functional mutations in undiagnosed individuals. P values 
for a Mann-Whitney test comparing each of the latter four distributions to that observed for 
the silent (synonymous) variants are plotted at the top of each violin.
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Figure 1. Excess of recurrently mutated genes
Each panel shows the observed number of recurrently mutated genes (diamond) and the 
distribution of the number of recurrently mutated genes in 10,000 simulations (box indicates 
interquartile range, whiskers indicates 95% confidence interval) under a model of no gene-
specific enrichment of mutations: a. all protein-altering mutations in all DDD children and 
undiagnosed DDD children, b. all LoF mutations in all DDD children and undiagnosed 
DDD children. Each diamond is annotated with the median excess of recurrently mutated 
genes, with 95% confidence intervals in brackets. P value of observed excess is <0.0001 for 
all four tests.
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Figure 2. Gene-specific significance of enrichment for DNMs
The –log10(p) value of testing for mutation enrichment is plotted only for each gene with at 
least one mutation in DDD children. On the X-axis is the p value of the most significant test 
in the DDD dataset, and on the Y-axis is the minimal p value from the significance testing in 
the meta-analysis dataset. Red indicates genes already known to be associated with DDs (in 
DDG2P). Only genes with a p value of less than 0.05/18,272 (red lines) are labeled.
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Figure 3. Five novel genes with clustered mutations
The domains (blue), post-translational modifications, and mutation locations (red stars) are 
shown for five proteins with highly clustered de novo mutations in unrelated children with 
severe, undiagnosed DDs. For two proteins (COL4A3BP and PCGF2) where all observed 
mutations are identical, photos are shown to highlight the facial similarities of patients 
carrying the same mutation.
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Figure 4. Candidate gene Loss of Function modeling in zebrafish reveals enrichment for 
developmentally important proteins
a, Examples of developmental phenotypes: Knockdown of pkn2a results in reduced 
cartilaginous jaw structures (black arrows), knockdown of fryl results in cardiac and 
craniofacial defects (white arrowheads and arrows, respectively), while knockdown of 
psmd3 results in smaller ear primordia (red arrows), and mis-patterned CNS neurons 
(compare red double arrows and brackets). b, Knockdown outcomes of 7 genes with variants 
present in microcephaly patients: Interocular measurements of brightfield images from 
control and LoF embryos reveal significant decreases in head size. A neuronal antibody stain 
(anti-HuC/D, green channel) labels the brains of control and morphant zebrafish. 
Measurements taken across the widest extent of the midbrain identify significant reductions 
in brain size, likely underlying the concomitant head size reductions seen in brightfield. In b, 
tables show average percentage reduction in head and brain width, and p-values of a t-test.
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Table 1
Breakdown of diagnoses by mode and by sex
Female (%) Male (%) Total (%)
Undiagnosed 383 (69.6%) 433 (74.3%) 816 (72.0%)
Diagnosed 167 (30.4%) 150 (25.7%) 317 (28.0%)
De novo mutation 124 (22.5%) 80 (13.7%) 204 (18.0%)
chrX 24 (4.4%) 5 (0.9%) 28 (2.6%)
autosomal 100 (18.2%) 75 (12.9%) 176 (15.5%)
Autosomal Dominant* 9 (1.6%) 11 (1.9%) 20 (1.8%)
Autosomal Recessive 20 (3.6%) 26 (4.5%) 46 (4.1%)
X-linked Inherited 1 (0.2%) 19 (3.3%) 20 (1.8%)
UPD/Mosaicism 4 (0.7%) 6 (1.0%) 10 (0.9%)
Composite 9 (1.6%) 8 (1.4%) 17 (1.5%)
Total 550 583 1133
*
Inherited from an affected parent
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Table 2
Novel genes with compelling evidence for a role in DD
Evidence Gene de novos DDD (Missense, 
LoF)
de novos Meta (Missense, 
LoF)
P Value Test Mutation Clustering Predicted Haploinsufficiency
De novo enrichment COL4A3BP 3 (3,0) 5 (5,0) 4.10E-12 Meta Yes 14.7%
PPP2R5D 4 (4,0) 5 (5,0) 6.01E-12 DDD Yes 19.7%
ADNP 4 (0,4) 5 (0,5) 4.59E-11 Meta No 9.8%
POGZ 2 (0,2) 5 (0,5) 4.31E-10 Meta No 30.0%
PPP2R1A 3 (3,0) 3 (3,0) 2.03E-08 DDD Yes 23.5%
DDX3X 4 (3,1) 5 (3,2) 2.26E-07 DDD No 12.7%
CHAMP1 2 (0,2) 3 (0,3) 4.58E-07 Meta No 52.9%
BCL11A 3 (3,0) 4 (3,1) 1.03E-06 DDD Yes 0.6%
PURA 3 (1,2) 3 (1,2) 1.14E-06 DDD No 9.4%
De novo enrichment + additional evidence DNM1 3 (3,0) 5 (5,0) 1.43E-06 Meta No 13.5%
TRIO 2 (2,0) 7 (7,0) 5.16E-06 Meta Yes 25.7%
PCGF2 2 (2,0) 2 (2,0) 1.08E-05 DDD Yes 37.7%
The table summarises the 12 genes with compelling evidence to be novel DD genes. The number of unrelated patients with independent functional or LoF mutations in the DDD cohort or the wider meta-
analysis dataset including DDD patients is listed. The p value reported is the minimum p value from the testing of the DDD dataset and the meta-analysis dataset. The dataset that gave this minimal p value 
is also reported. Mutations are considered to be clustered if the p value of clustering of functional SNVs is less than 0.01. Predicted haploinsufficiency is reported as a percentile of all genes in the genome, 
with ~0% being highlight likely to be haploinsufficient and 100% very unlikely to be haploinsufficient, based on the prediction score described in Huang et al 26 updated to enable predictions for a higher 
fraction of genes in the genome. During submission, a paper was published online describing a novel DD caused by mutations in ADNP 27.
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